Advent Pharma Ltd. (DSE:ADVENT)
13.60
-0.10 (-0.73%)
At close: May 6, 2026
Advent Pharma Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 458.15 | 500.49 | 571.67 | 558.05 | 530.47 | 503.6 | |
Revenue Growth (YoY) | -4.35% | -12.45% | 2.44% | 5.20% | 5.34% | -5.70% |
Cost of Revenue | 319.1 | 324.86 | 343.77 | 335.14 | 310.31 | 288 |
Gross Profit | 139.05 | 175.63 | 227.9 | 222.91 | 220.16 | 215.61 |
Selling, General & Admin | 67.41 | 80.04 | 86.26 | 87.55 | 86.78 | 79.18 |
Operating Expenses | 67.41 | 80.04 | 86.26 | 87.55 | 86.78 | 79.18 |
Operating Income | 71.64 | 95.58 | 141.65 | 135.36 | 133.38 | 136.42 |
Interest Expense | -9.48 | -9.16 | -8.09 | -6.63 | -4.11 | -4.9 |
Interest & Investment Income | 0.02 | 0.02 | 0.02 | 0.01 | 1.1 | 2.93 |
Other Non Operating Income (Expenses) | -0.17 | -0.16 | -0.18 | -0.11 | -0.08 | 0.12 |
EBT Excluding Unusual Items | 62.01 | 86.29 | 133.39 | 128.63 | 130.3 | 134.58 |
Gain (Loss) on Sale of Assets | - | - | -29.61 | - | - | -0.39 |
Pretax Income | 62.01 | 86.29 | 103.78 | 128.63 | 130.3 | 134.19 |
Income Tax Expense | 13.98 | 19.41 | 19.79 | 29.99 | 32.76 | 20.6 |
Net Income | 48.03 | 66.87 | 83.99 | 98.64 | 97.53 | 113.59 |
Net Income to Common | 48.03 | 66.87 | 83.99 | 98.64 | 97.53 | 113.59 |
Net Income Growth | -1.34% | -20.38% | -14.85% | 1.14% | -14.14% | -2.96% |
Shares Outstanding (Basic) | 93 | 93 | 93 | 93 | 93 | 93 |
Shares Outstanding (Diluted) | 93 | 93 | 93 | 93 | 93 | 93 |
Shares Change (YoY) | -0.62% | - | - | - | - | - |
EPS (Basic) | 0.52 | 0.72 | 0.90 | 1.06 | 1.05 | 1.22 |
EPS (Diluted) | 0.52 | 0.72 | 0.90 | 1.06 | 1.05 | 1.22 |
EPS Growth | -0.73% | -20.38% | -14.85% | 1.14% | -14.14% | -2.96% |
Free Cash Flow | 0.25 | 20.56 | 13.08 | 2.56 | -11.56 | -3.67 |
Free Cash Flow Per Share | 0.00 | 0.22 | 0.14 | 0.03 | -0.12 | -0.04 |
Dividend Per Share | 0.050 | 0.050 | 0.100 | 0.200 | 0.200 | 0.196 |
Dividend Growth | -50.00% | -50.00% | -50.00% | - | 1.99% | - |
Gross Margin | 30.35% | 35.09% | 39.87% | 39.95% | 41.50% | 42.81% |
Operating Margin | 15.64% | 19.10% | 24.78% | 24.26% | 25.14% | 27.09% |
Profit Margin | 10.48% | 13.36% | 14.69% | 17.68% | 18.39% | 22.56% |
Free Cash Flow Margin | 0.06% | 4.11% | 2.29% | 0.46% | -2.18% | -0.73% |
EBITDA | 134.17 | 158.05 | 207.57 | 193.96 | 175.07 | 174.59 |
EBITDA Margin | 29.29% | 31.58% | 36.31% | 34.76% | 33.00% | 34.67% |
D&A For EBITDA | 62.53 | 62.47 | 65.93 | 58.6 | 41.69 | 38.17 |
EBIT | 71.64 | 95.58 | 141.65 | 135.36 | 133.38 | 136.42 |
EBIT Margin | 15.64% | 19.10% | 24.78% | 24.26% | 25.14% | 27.09% |
Effective Tax Rate | 22.55% | 22.50% | 19.07% | 23.31% | 25.15% | 15.35% |
Advertising Expenses | - | 0.12 | 0.15 | 0.19 | 0.18 | 0.15 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.